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OBJECTIVES: To estimate the annual per patient cost of Amyotrophic Lateral Scle-
rosis (ALS) in Greece from a societal point of view. METHODS: Data on direct costs
(medications, laboratory/imaging tests, consultations, hospitalizations) were ob-
tained through retrospective chart review of a sample of patients followed-up in
Aeginition University Hospital, a reference centre for ALS in Greece. Eligible pa-
tients were those that visited the ALS clinic in the previous 6 months and had fully
recorded data for the previous year. Patients were also personally interviewed,
following consent, based on a strictly-structured questionnaire, with an aim to
record indirect costs incurred in the previous year (work absenteeism, professional
home help, walking aids). Unit prices for health-resource use were the official NHS
prices. Work loss and home help were costed with the hourly rate of the basic
salary, in order to obtain a conservative approach. Costs are reported in year 2011
Euros. RESULTS: The sample (N34) was 53% female with an average age of 61.6
years. Total average annual per patient cost was 7450.6€ (standard deviation:
6423€), out of which 4136.3€ (s.d. 1,350€) were direct and 3314.2€ (s.d. 6190€) were
indirect expenditure. Medications accounted for 32.7% of the total cost, followed by
professional home help (24.4%), work absenteeism (17.7%) and hospitalizations
(9.2%). Women had a significantly higher average cost than men (10,004€ vs. 4,347€,
p0.05), mostly as a result of indirect expenditures from productivity loss. Age65
did not have a significant impact on outcomes due to the substitution of produc-
tivity losses (65) by home help, for patients 65. CONCLUSIONS: ALS entails a
significant per patient economic burden in societal terms. Cost-of-illness data,
even for rare diseases, provide important inputs for the decision-making process in
health as well as for awareness purposes.
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OBJECTIVES: Alzheimer’s disease (AD) is the most common form of dementia.
Estimates of the cost of AD in Romania come from external sources and are based
on extrapolations and assumptions. We tried to replace some of the assumptions
with actual data obtained from official sources and based on data obtained from
the Bucharest Memory Center. METHODS: This is an empirical investigation of the
economic cost of AD in Romania in 2010. Direct and indirect costs are estimated
and allocated to the AD by taking in consideration an extrapolation of European
data for incidence and prevalence, actual cost for medication provided by National
Insurance House for specific medication used in prevention an treatment of AD,
actual data provided by Ministry of Labor and Social Security for persons with AD
living in nursing home. Cost of care provided by family members were estimated
on a telephonic cross-sectional survey, carried out using the database of Bucharest
Memory Center. RESULTS: The calculated cost of Alzheimer’s disease in Romania
is 187.022.387 €, direct medical cost of 62 millions €, 7.5 million € for hospitalization,
medication of 34.9 million €, ambulatory medical services of 0.4 million €, nursing
home costs of 4.6 million €, parapharmaceuticals cost of 15 million € and indirect
(informal) cost of 124.5 million €. CONCLUSIONS: There is a major discrepancy
between the cost obtained by Wimo A. et al in 2010 and ours, which is 10 times
smaller. The main difference is due the small number of people hospitalized in
specialized centers, only 3%, the small number of people receiving treatment - only
14% of the total number of patients with DA. Romania must strive to remove the
inequities concerning informal costs and be prepared for an exponentially increase
of costs as the care of patients will normalize.
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OBJECTIVES: To estimate the annual per patient cost of Myasthenia Gravis (MG) in
Greece from a societal perspective. METHODS: Data on direct costs (medications,
laboratory/imaging tests, consultations, hospitalizations) were obtained through
retrospective chart review of a sample of patients followed-up in Aeginition Uni-
versity Hospital, a reference centre for MG in Greece. Eligible patients were those
that visited the MG clinic in the previous 6 months and had fully recorded data for
the previous year. Patients were also personally interviewed, following consent,
based on a strictly-structured questionnaire, with an aim to record indirect costs
incurred in the previous year (premature retirement, work absenteeism, decreased
productivity, professional home help). Unit prices for health-resource use were the
official NHS prices. Productivity losses and home help were costed with the hourly
rate of the basic salary, in order to obtain a conservative approach. Costs are re-
ported in year 2011 Euros. RESULTS: The sample (N32) was 56% female with an
average age of 57 years (men: 66.6, women: 49.5). Average total annual per patient
cost was 4125.4€ (standard deviation: 5287€), out of which 614.3€ (s.d.: 496€) were
direct and 3511.5€ (s.d.: 5260.5€) were indirect expenditure. Early retirement, home
help, and medications were the major cost drivers of total cost (49%, 31% and 8%
respectively), while medications had the biggest influence when focusing on direct
costs alone (51%). Women had a higher average cost than men (5173€ vs. 2777€),
principally as a result of indirect expenditures from lost productivity.
CONCLUSIONS: MG is a burdensome disease, in socioeconomic terms, that seems
to affect women more heavily, compared to men, most probably due to symptom
onset at a younger (and more productive) age. Even in the case of low prevalence-
or rare-diseases, cost-of-illness analysis can promote awareness and contribute
with the necessary data to health policy decisions.
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OBJECTIVES: Multiple sclerosis (MS) is a prevalent, chronic and disabling disease,
mainly affecting young adults. The aim of the present work is to analyse the cost of
the informal care of MS according to disability, in different Spanish regions.
METHODS: Patients with clinical diagnosis of MS, from different Spanish regions,
were selected between december 2006 and december 2010. The patients were di-
vided in 3 groups based on their disability: mild (EDSS 0-3,5), moderate (EDSS 4,0-
6,5) and severe (7,0-9,5). They were invited to answer a questionnaire, with demo-
graphic, social, employment status data, clinical aspects, as well as data about the
consumption of sanitary and no-sanitary resources during the MS process. The
replacement method was used to estimate informal costs. RESULTS: We analized
1107 pacients and 317 caregivers. The percentage of patients requiering informal
care increased with disability, ranging from 7% (mild disability) to 73% (severe
disability) and daily hours of informal care per patient, 0.4 (mild disability) to 11.8
(severe disability). These informal cares can also vary depending on the Spanish
region analyzed. The caregiver mean age was 53 years, is mostly the patient’s
partner (54%) and has been practicing as a caregiver a mean of 10 years. The esti-
mated cost of informal care increased with disability, ranging from 777 euros/
patient/year (mild disability) to 26.987 euros/patient/year (severe disability). The
cost grew to 45% of the total cost of the disease in advanced stages. CONCLUSIONS:
The estimated cost of informal care increased with disability, ranging from 777
euros/patient/year (mild disability) to 26,987 euros/patient/year (severe disability).
It represented almost half of the total cost of the disease in advanced stages.
PND24
COST OF SYMPTOMATIC DRUG THERAPY IN MULTIPLE SCLEROSIS
Fogarty E, Tilson L, Barry M
National Centre for Pharmacoeconomics, Dublin, Ireland
OBJECTIVES: Drug therapy in Multiple Sclerosis (MS) accounts for a significant
proportion of the economic burden of this disease. Expenditure on disease-modi-
fying-therapies (DMT) in Ireland was €32.7 million in 2009, 1.63% of total pharma-
ceutical expenditure. In addition to DMT, other non-DMT drugs are used to treat MS
symptoms. This study describes the patterns and cost of non-DMT (other) drug
utilisation in Ireland.METHODS:A cohort of patients dispensed a DMT during 2009
were identified from a national prescribing database. An analysis of all other drugs
dispensed for this cohort during 2009 was undertaken. RESULTS: A cohort of 2749
people on DMT was identified (39.3% of the estimated Irish MS population) 69.0% of
whom also received other drugs costing €2.7 million (estimated 7.6% of total MS
drug costs). The mean other drug cost per person on DMT was €1417 (SD €1863).
Drug classes contributing most to other drug costs were antiepileptics (17.1%) used
for neuropathic pain, urinary antispasmodics (8.1%) and muscle relaxants (7.0%).
The top 10 drugs by cost included pregabalin, gabapentin, modafinil, tizandine,
tolterodine, evening primrose oil, atorvastatin, venlafaxine, baclofen and escitalo-
pram (39.9% of other drug costs). The most commonly prescribed drug classes –
antidepressants, analgesics and NSAIDs, dispensed to over 20% of the cohort in
each case, accounted for just 12.7% of other drug costs. CONCLUSIONS: Character-
isation of non-DMT drug use provides useful information for clinicians, healthcare
payers, and those undertaking cost-of-illness studies. While these drugs account
for a smaller proportion of overall costs than DMT, they are an indication of overall
morbidity and wider resource utilisation e.g. urological drugs as an indicator for
physiotherapy and incontinence equipment. These results can be considered in
the design of future cost-of-illness surveys which often include an exhaustive list
of individual drugs.
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OBJECTIVES: Population characteristics of patients with epilepsy remain poorly
documented in France. Reimbursement databases may be useful to perform cost
and epidemiological studies provided that patient diagnoses can be identified ei-
ther directly, or indirectly through the use of antiepileptic drugs (AEDs) as markers.
This study explored the possibility to use the French reimbursement database to
determine the prevalence and direct cost of epilepsy. METHODS: The “EGB” reim-
bursement database is a 1/97 representative sample (500,000 individuals) of the
population covered under the French General Scheme. Only a fraction of patients
fully covered for epilepsy can be identified on a diagnosis basis. The rest of them
can only be identified through their treatment by AEDs, but some are not specific to
epilepsy (e.g. benzodiazepines). An algorithm was built to identify patients with
epilepsy and calculate an estimation of the prevalence. In parallel, total medical
expenses of patients were derived on the fully covered sub-population. RESULTS:
Only patients treated with polytherapy (2 AEDs) could be identified in a relevant
way by an algorithm based on drug use. The prevalence of epilepsy in this sub-
group in 2009 was estimated between 1.83‰ and 2.79‰ (93,000 – 142,000 patients).
A proportion of 70.1% to 71.6% were fully covered by insurance for their expenses,
with epilepsy alone as a cause in only 27 to 33% of them. The most frequent
comorbidities were psychiatric disorders and incapacitating stroke. The annual per
capita expenses were in the range of 6601€- 6696€ for patients with polytherapy,
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inpatient care and drug costs represented about 50% and 27% respectively of over-
all expenses. The increase by 24.4% polytherapy patients mean costs as compared
to monotherapy raised to 72% [IC 95: 44-106%] after adjustment on age, gender and
presence of severe comorbidity. CONCLUSIONS: Polytherapy in epilepsy is associ-
ated with substantial higher direct costs.
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OBJECTIVES: To develop a tool to estimate the first-year per member and total
health plan costs associated with monitoring of MS therapies in the United States.
METHODS: Data were incorporated into an interactive tool designed to allow a
health plan to estimate their costs for monitoring. MS prevalence was based on the
literature. The default value for the proportion of MS patients treated with immu-
nomodulators was assumed at 95% and adjusted IMS data were used for default
market share inputs. Current Procedural Terminology (CPT) codes corresponding
to the monitoring and administration procedures recommended by each product’s
prescribing information (PI) were identified. Charges associated with each CPT
code were assigned using physician fee schedule software based on Medicare
charges with default values set at 150%. PI recommendations were used for the
proportion being monitored and the frequency of monitoring. In cases where a PI
recommended only individuals with specific characteristics undergo monitoring, a
database analysis identifying all individuals with a diagnosis of MS in the i3 InVi-
sion Data Mart (Ingenix, Eden Prairie, MN) was used to estimate the proportion of
patients who may require that specific monitoring. RESULTS: The tool yielded
average per patient and health plan costs expected with MS therapy monitoring.
The tool conservatively estimates that the average per member first-year monitor-
ing and administration costs ranged from $0 for glatiramer acetate to $3279 for
natalizumab. Based on default values, the estimated annual costs of monitoring for
all MS therapies for a million member health plan is $519,451. CONCLUSIONS:
Estimating the economic impact of FDA-recommended MS therapy monitoring
allows health plans to more closely assess the total cost of MS. This tool allows
health plans to individualize inputs to estimate the plan-specific economic impact
of MS therapy monitoring.
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OBJECTIVES: Botulinum toxin A (BTA) injections are indicated for the management
of neurological movement disorders, including arm spasticity (AS) and cervical
dystonia (CD). This study calculated the cost per care episode for two BTA: Botox®
and Dysport®. The analysis was completed for 20 countries around the world.
METHODS: Doses of BTA are expressed in non-interchangeable units: Botox® is
available in “Allergan units” whereas Dysport® is provided in 500 “Speywood
units”. Recommended dosages were derived from country SmPCs/PIs. Cost analy-
sis was based on official list prices and expressed in 2011 euros, using exchange
rates as of end of May 2011. The cost per care episode was calculated using avail-
able recommended dosages for each product (country’s own or average of other
countries) combined with price per vial in each country. RESULTS: For AS, recom-
mended total injection dosage per patient for Dysport is 1000 units in all countries
where indicated in SmPCs; for Botox®, it is 300U per patient based on recom-
mended dosages in the USA and France. For CD, dosages for Dysport® are 500U per
patient; whereas 200U of Botox® is recommended per patient. Considered with the
respective prices per vial in each country, Dysport® cost per patient per care epi-
sode for AS was less than Botox® in 17 (89%) of the 19 countries (average 15% less
across countries). The difference was 20% or higher in nearly half (47%) of coun-
tries. In CD, these differences were even greater with Dysport® cost per patient was
40% or less versus Botox in 45% of countries (average 36% less across countries).
CONCLUSIONS: Considering cost per patient per care episode based on recom-
mended dosages in SmPCs/PIs, Dysport® remains cheaper versus Botox in most
countries. When extrapolated to a national level, substantial savings could be re-
alized by using Dysport® in the treatment of AS and CD.
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OBJECTIVES: The aim of this study was to calculate the incremental cost-effective-
ness ratio of the different Disease Modifying Drugs (DMD) used as first-line treat-
ments (interferons IM IFN-1a, SC IFN-1a, SC IFN-1b and glatiramer acetate, GA)
in Remitting-Relapsing Multiple Sclerosis (RRMS) in Spain. METHODS: A Markov
model was developed to simulate the progression of a cohort of patients with
RRMS, during a period of 10 years. Seven health states, defined by the EDSS, were
considered in the model. Patients with an EDSS score of less than 6.0 were assumed
to be treated with one of DMD. In addition, all patients were assumed to receive
symptomatic treatment. The monthly transition probabilities of the model were
obtained from the literature. The analysis was performed from the societal per-
spective, in which both direct and indirect (losses in productivity) healthcare costs
(€, 2010) were included. A discount rate of 3% was applied to both costs and results.
RESULTS: GA was the less costly strategy (€322,510), followed by IM IFN-1a (€
329.595), SC IFN-1b (€ 333.925) and SC IFN-1a (€ 348.208). IM IFN-1a has
shown the best efficacy results with 4,176 quality-adjusted life year (QALY),
followed by SC IFN-1a (4,158 QALY), SC IFN-1b (4,157 QALY) and GA (4,117
QALY). Incremental costs per QALY gained with IM IFN-1a were €-1,005,194/
QALY, €-223,397/QALY, and €117,914/QALY in comparison to SC IFN-1a, SC
IFN-1b and GA, respectively. CONCLUSIONS: First-line treatment with GA is the
less costly strategy for the treatment of patients with RRMS. Treatment with IM
IFN-1a is a dominant strategy (lower cost and higher QALY) compared with SC
IFN-1a and SC IFN-1b. However, IM IFN-1a is not a cost-effective strategy versus
GA, because incremental cost per QALY gained with IM IFN-1a exceeds the €30,000
per QALY threshold, commonly used in Spain.
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OBJECTIVES: Multiple sclerosis (MS) is the neurologic disability that can dramati-
cally affect the quality of life (QoL) of patients and their families. Family life, eco-
nomic status, and social interaction may be affected by somatic symptoms of the
disease. Approximately 70,000 people in the Islamic Republic of Iran are affected by
MS. Under budgetary constraints,Cost-effectiveness and cost-utility analyses
(CEA/CUAs) are useful tools to assess the tradeoff between the added costs and
potential benefits (e.g., improved patient outcomes) of new therapies. METHODS:
The primary objective of this analysis was to evaluate the cost-effectiveness of
Avonex compared with Betaferon from the Iranian Ministry of Health(MoH) over a
2-year time horizon. The relative risk reduction (RRR) method was used to compare
reduction in relapse rates and disease progression data from pivotal randomized
double-blind placebo-controlled clinical trials of the DMDs. The evaluation was
conducted from the perspective of a Iranian health care sector (direct medical costs
and indirect cost considered). The primary economic endpoint was cost per relapse
avoided . Costs and outcomes occurring in the second year were discounted 3% to
bring to 2010 present values. One way sensitivity analyses were conducted on key
input variables to assess their impact on cost per relapse avoided. RESULTS: The
2-year reductions in clinical relapses for treatment with Avonex,Betaferon were
0.69 and 0.60 relatively. In the base case analysis, Avonex had the most favorable
costs per relapse avoided (2652778 Rials) rather than Betaferon. Sensitivity analy-
ses showed that these results were robust to changes in key input parameters, such
as the number of relapses and disease progression steps in untreated patients, the
progression rates, the average cost of relapse. CONCLUSIONS: This evaluation sug-
gests that IFN -1a SC injection(Avonex) represent the most cost-effective DMDs
for the treatment of RRMS, where cost-effectiveness is defined as cost per relapse
avoided,rather than Bataferon.
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OBJECTIVES: Early intervention in the course of acute migraine attacks has been
recently advocated as a way to further reduce the economic burden and suffering
of patients due to this condition. The aim of this study was to investigate the
cost-effectiveness of such a strategy using almotriptan in the Spanish setting.
METHODS: An economic evaluation was conducted from the Spanish societal and
public health system perspective based on patient-level data collected in the “Act
when Mild” study. Incremental cost-effectiveness ratios (ICER) were determined in
terms of attack duration, loss of productive time and quality-adjusted life days
(QALDs). Monte Carlo simulation was used to derive cost-effectiveness acceptabil-
ity curves. RESULTS: Early treatment led on average to shorter attack duration, less
productive time lost, better quality of life, and was overall cost-saving from a
societal point of view with a probability of 97%. In terms of publicly reimbursed
drug costs only, though, non-early treatment was always slightly less expensive.
From the public health system perspective the (bootstrap) mean ICER of early treat-
ment amounted to €0.12 per migraine hour avoided, €0.42 per hour of productive
time lost avoided, and €6.62 per QALD gained. Considering willingness to pay val-
ues of €1 to reduce attack duration by one hour, €5 to avoid the loss of one produc-
tive hour, or €55 to gain one QALD (equivalent to €20,000 per QALY), the probability
that early treatment was cost-effective from the public health system perspective
was, respectively, 96%, 96%, and 98%. These results remained robust in sensitivity
analyses that accounted for the uncertainty surrounding the major elements of the
economic evaluation. CONCLUSIONS: Compared to non-early treatment, early
treatment of acute migraine attacks with almotriptan when pain is still mild is with
high probability cost-saving from the Spanish societal perspective and cost-effec-
tive from the public health system point of view.
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